WO2009086116A3 - Alternative scaffold protein fusions phage display via fusion to plx of m13 phage - Google Patents

Alternative scaffold protein fusions phage display via fusion to plx of m13 phage Download PDF

Info

Publication number
WO2009086116A3
WO2009086116A3 PCT/US2008/087696 US2008087696W WO2009086116A3 WO 2009086116 A3 WO2009086116 A3 WO 2009086116A3 US 2008087696 W US2008087696 W US 2008087696W WO 2009086116 A3 WO2009086116 A3 WO 2009086116A3
Authority
WO
WIPO (PCT)
Prior art keywords
phage
plx
scaffold protein
protein fusions
display via
Prior art date
Application number
PCT/US2008/087696
Other languages
French (fr)
Other versions
WO2009086116A2 (en
Inventor
Steven Jacobs
Original Assignee
Centocor, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centocor, Inc. filed Critical Centocor, Inc.
Priority to EP08868131A priority Critical patent/EP2238247A2/en
Priority to CA2709994A priority patent/CA2709994A1/en
Priority to AU2008345674A priority patent/AU2008345674A1/en
Priority to JP2010539875A priority patent/JP2011507529A/en
Publication of WO2009086116A2 publication Critical patent/WO2009086116A2/en
Publication of WO2009086116A3 publication Critical patent/WO2009086116A3/en
Priority to IL206409A priority patent/IL206409A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/02—Libraries contained in or displayed by microorganisms, e.g. bacteria or animal cells; Libraries contained in or displayed by vectors, e.g. plasmids; Libraries containing only microorganisms or vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1044—Preparation or screening of libraries displayed on scaffold proteins

Abstract

The invention relates to compositions and methods for generating and using plX phage display libraries for producing non-antibody scaffold protein fusions using plX of M13 phage.
PCT/US2008/087696 2007-12-19 2008-12-19 Alternative scaffold protein fusions phage display via fusion to plx of m13 phage WO2009086116A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
EP08868131A EP2238247A2 (en) 2007-12-19 2008-12-19 Alternative scaffold protein fusions phage display via fusion to plx of m13 phage
CA2709994A CA2709994A1 (en) 2007-12-19 2008-12-19 Non-antibody scaffold protein fusions phage display via fusion to pix of m13 phage
AU2008345674A AU2008345674A1 (en) 2007-12-19 2008-12-19 Alternative scaffold protein fusions phage display via fusion to pIX of M13 phage
JP2010539875A JP2011507529A (en) 2007-12-19 2008-12-19 Alternative scaffold protein fusion phage display via fusion of M13 phage to pIX
IL206409A IL206409A0 (en) 2007-12-19 2010-06-16 ALTERNATIVE SCAFFOLD PROTEIN FUSIONS PHAGE DISPLAY VIA FUSION TO pIX OF M13 PHAGE

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1477807P 2007-12-19 2007-12-19
US61/014,778 2007-12-19

Publications (2)

Publication Number Publication Date
WO2009086116A2 WO2009086116A2 (en) 2009-07-09
WO2009086116A3 true WO2009086116A3 (en) 2009-10-08

Family

ID=40825038

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/087696 WO2009086116A2 (en) 2007-12-19 2008-12-19 Alternative scaffold protein fusions phage display via fusion to plx of m13 phage

Country Status (6)

Country Link
EP (1) EP2238247A2 (en)
JP (1) JP2011507529A (en)
AU (1) AU2008345674A1 (en)
CA (1) CA2709994A1 (en)
IL (1) IL206409A0 (en)
WO (1) WO2009086116A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9593339B1 (en) 2013-02-14 2017-03-14 David Gordon Bermudes Bacteria carrying bacteriophage and protease inhibitors for the treatment of disorders and methods of treatment

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004296376B2 (en) 2003-12-05 2010-03-04 Bristol-Myers Squibb Company Inhibitors of type 2 vascular endothelial growth factor receptors
US20080124355A1 (en) 2006-09-22 2008-05-29 David Gordon Bermudes Live bacterial vaccines for viral infection prophylaxis or treatment
BRPI0719597A2 (en) 2006-11-22 2013-12-17 Adnexus A Bristol Myers Squibb R & D Company OBJECTIVE THERAPEUTIC PRODUCTS BASED ON HANDLED PROTEINS FOR TYROSINE KINASE RECEPTORS, INCLUDING IGF-IR
WO2009102421A2 (en) 2008-02-14 2009-08-20 Bristol-Myers Squibb Company Targeted therapeutics based on engineered proteins that bind egfr
JP2011520961A (en) 2008-05-22 2011-07-21 ブリストル−マイヤーズ スクイブ カンパニー Scaffold domain protein based on multivalent fibronectin
US8647642B2 (en) 2008-09-18 2014-02-11 Aviex Technologies, Llc Live bacterial vaccines resistant to carbon dioxide (CO2), acidic PH and/or osmolarity for viral infection prophylaxis or treatment
PL2356269T3 (en) 2008-10-31 2016-12-30 Fibronectin type iii domain based scaffold compositions, methods and uses
TWI496582B (en) 2008-11-24 2015-08-21 必治妥美雅史谷比公司 Bispecific egfr/igfir binding molecules
US8241623B1 (en) 2009-02-09 2012-08-14 David Bermudes Protease sensitivity expression system
US8771669B1 (en) 2010-02-09 2014-07-08 David Gordon Bermudes Immunization and/or treatment of parasites and infectious agents by live bacteria
US9597379B1 (en) 2010-02-09 2017-03-21 David Gordon Bermudes Protease inhibitor combination with therapeutic proteins including antibodies
US8524220B1 (en) 2010-02-09 2013-09-03 David Gordon Bermudes Protease inhibitor: protease sensitivity expression system composition and methods improving the therapeutic activity and specificity of proteins delivered by bacteria
EP3569256B1 (en) * 2010-04-30 2022-06-15 Janssen Biotech, Inc. Stabilized fibronectin domain compositions, methods and uses
TW201138808A (en) 2010-05-03 2011-11-16 Bristol Myers Squibb Co Serum albumin binding molecules
US9562089B2 (en) 2010-05-26 2017-02-07 Bristol-Myers Squibb Company Fibronectin based scaffold proteins having improved stability
PT2697257T (en) 2011-04-13 2016-12-28 Bristol Myers Squibb Co Fc fusion proteins comprising novel linkers or arrangements
EP2709669A1 (en) 2011-05-17 2014-03-26 Bristol-Myers Squibb Company Methods for maintaining pegylation of polypeptides
EP3318880B1 (en) 2011-05-17 2020-12-16 Bristol-Myers Squibb Company Improved methods for the selection of binding proteins
EP3540100B8 (en) 2011-09-27 2022-11-02 Janssen Biotech, Inc. Fibronectin type iii repeat based protein scaffolds with alternative binding surfaces
US9522951B2 (en) 2011-10-31 2016-12-20 Bristol-Myers Squibb Company Fibronectin binding domains with reduced immunogenicity
CN104768969B (en) 2012-09-13 2021-04-16 百时美施贵宝公司 Fibronectin based scaffold domain proteins that bind to myostatin
US20150361159A1 (en) 2013-02-01 2015-12-17 Bristol-Myers Squibb Company Fibronectin based scaffold proteins
EP3406629B1 (en) 2013-02-06 2020-06-24 Bristol-Myers Squibb Company Fibronectin type iii domain proteins with enhanced solubility
US10065987B2 (en) 2013-02-12 2018-09-04 Bristol-Myers Squibb Company High pH protein refolding methods
WO2014126871A1 (en) 2013-02-12 2014-08-21 Bristol-Myers Squibb Company Tangential flow filtration based protein refolding methods
EP2968587A2 (en) 2013-03-13 2016-01-20 Bristol-Myers Squibb Company Fibronectin based scaffold domains linked to serum albumin or a moiety binding thereto
US9737592B1 (en) 2014-02-14 2017-08-22 David Gordon Bermudes Topical and orally administered protease inhibitors and bacterial vectors for the treatment of disorders and methods of treatment
MX2016011580A (en) 2014-03-20 2016-11-29 Bristol Myers Squibb Co Serum albumin-binding fibronectin type iii domains.
EP3647322B1 (en) 2014-03-20 2021-10-20 Bristol-Myers Squibb Company Stabilized fibronectin based scaffold molecules
CN107207379B (en) 2014-11-25 2021-08-10 百时美施贵宝公司 For biological products18Methods and compositions for F-radiolabelling
CN115043943A (en) 2015-05-15 2022-09-13 综合医院公司 Antagonistic anti-tumor necrosis factor receptor superfamily antibodies
EP3708580B1 (en) 2015-09-23 2023-11-01 Bristol-Myers Squibb Company Fast-off rate serum albumin binding fibronectin type iii domains
US10994033B2 (en) 2016-06-01 2021-05-04 Bristol-Myers Squibb Company Imaging methods using 18F-radiolabeled biologics
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
US10626165B2 (en) 2016-12-14 2020-04-21 Janssen Biotech, Inc. CD8a-binding fibronectin type III domains
EP3554535A4 (en) 2016-12-14 2020-10-21 Janssen Biotech, Inc. Pd-l1 binding fibronectin type iii domains
WO2018111978A1 (en) 2016-12-14 2018-06-21 Janssen Biotech, Inc. Cd137 binding fibronectin type iii domains
US11628222B2 (en) 2019-10-14 2023-04-18 Aro Biotherapeutics Company CD71 binding fibronectin type III domains
WO2021076574A2 (en) 2019-10-14 2021-04-22 Aro Biotherapeutics Company Fn3 domain-sirna conjugates and uses thereof
JP2023515633A (en) 2020-02-28 2023-04-13 ブリストル－マイヤーズ スクイブ カンパニー Radiolabeled fibronectin-based scaffolds and antibodies and their theranostic uses

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030148263A1 (en) * 1997-08-29 2003-08-07 Selective Genetics, Inc. Methods and compositions using genetic package display

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030148263A1 (en) * 1997-08-29 2003-08-07 Selective Genetics, Inc. Methods and compositions using genetic package display

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
HU ET AL.: "Phage display selection of peptides that inhibit metastasis ability of gastric cancer cells with high liver-metastatic potential.", BIOCHEM BIOPHYS RES COMMUN., vol. 341, no. 4, 2006, pages 964 - 972, Retrieved from the Internet <URL:http://www.ncbi.nlm.nih.gov/sites/entrez> [retrieved on 20090720] *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9593339B1 (en) 2013-02-14 2017-03-14 David Gordon Bermudes Bacteria carrying bacteriophage and protease inhibitors for the treatment of disorders and methods of treatment

Also Published As

Publication number Publication date
AU2008345674A1 (en) 2009-07-09
IL206409A0 (en) 2010-12-30
CA2709994A1 (en) 2009-07-09
WO2009086116A2 (en) 2009-07-09
EP2238247A2 (en) 2010-10-13
JP2011507529A (en) 2011-03-10

Similar Documents

Publication Publication Date Title
WO2009086116A3 (en) Alternative scaffold protein fusions phage display via fusion to plx of m13 phage
MX2009009773A (en) Substituted heterocycle fused gamma-carbolines synthesis.
WO2009058379A3 (en) Protein scaffolds
GB2468232A (en) Antigen-bindng constructs
WO2009055512A3 (en) Methods and compostions for obtaining high-resolution crystals of membrane proteins
WO2008121767A3 (en) Stitched polypeptides
DE602005015519D1 (en) Process for increasing the foamability of spray-dried powders
WO2008060705A8 (en) Anti-dll4 antibodies and methods using same
WO2007127841A3 (en) Compositions and methods of preparation thereof
CA2705357C (en) Formulations for taci-immunoglobulin fusion proteins
JO2778B1 (en) Certain Compounds, Compositions and Methods
WO2008054543A3 (en) Oligonucleotides for multiplex nucleic acid assembly
WO2006127898A3 (en) (s)-n-methylnaltrexone, process for its synthesis and its pharmaceutical use
WO2007120766A3 (en) Erythropoietin receptor agonists
WO2008089022A3 (en) Cd200 and its receptor, cd200r, modulate bone mass via the differentiation of osteoclasts
EP1948804A4 (en) Methods of making modular fusion protein expression products
WO2009067578A3 (en) New vitamin d receptor activators and methods of making
WO2010021738A3 (en) Method for producing double-crosslinked collagen
WO2010068282A3 (en) Compositions and methods for synthesis of hydrogen fuel
WO2008085900A3 (en) Methods for generating novel stabilized proteins
WO2009002440A3 (en) Compositions comprising human egfr-sirna and methods of use
ZA200705216B (en) Novel process for the preparation of substituted indoles
NO20074277L (en) Kinnolin compounds and their use as liver X receptor modulators
WO2010057088A3 (en) Pyrrolidinyl modulators of nicotinic acetylcholine receptors
WO2009035959A3 (en) Radiofluorination methods

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08868131

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2008345674

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2709994

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2010539875

Country of ref document: JP

Ref document number: 2216/KOLNP/2010

Country of ref document: IN

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2008345674

Country of ref document: AU

Date of ref document: 20081219

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2008868131

Country of ref document: EP